- Home
- ALMS vs RIGL Comparison
ALMS vs RIGL Comparison
Compare ALMS & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALMS
- RIGL
- Stock Information
- Founded
- ALMS 2021
- RIGL 1996
- Country
- ALMS United States
- RIGL United States
- Employees
- ALMS N/A
- RIGL N/A
- Industry
- ALMS
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ALMS
- RIGL Health Care
- Exchange
- ALMS NYSE
- RIGL Nasdaq
- Market Cap
- ALMS 469.0M
- RIGL 486.4M
- IPO Year
- ALMS 2024
- RIGL 2000
- Fundamental
- Price
- ALMS $7.41
- RIGL $21.81
- Analyst Decision
- ALMS Strong Buy
- RIGL Buy
- Analyst Count
- ALMS 6
- RIGL 5
- Target Price
- ALMS $29.60
- RIGL $34.80
- AVG Volume (30 Days)
- ALMS 121.0K
- RIGL 347.9K
- Earning Date
- ALMS 02-15-2025
- RIGL 03-04-2025
- Dividend Yield
- ALMS N/A
- RIGL N/A
- EPS Growth
- ALMS N/A
- RIGL N/A
- EPS
- ALMS N/A
- RIGL 0.22
- Revenue
- ALMS N/A
- RIGL $157,374,000.00
- Revenue This Year
- ALMS N/A
- RIGL $51.34
- Revenue Next Year
- ALMS N/A
- RIGL $15.75
- P/E Ratio
- ALMS N/A
- RIGL $98.50
- Revenue Growth
- ALMS N/A
- RIGL 21.65
- 52 Week Low
- ALMS $6.75
- RIGL $7.48
- 52 Week High
- ALMS $13.53
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- ALMS N/A
- RIGL 64.53
- Support Level
- ALMS N/A
- RIGL $17.28
- Resistance Level
- ALMS N/A
- RIGL $18.25
- Average True Range (ATR)
- ALMS 0.00
- RIGL 1.37
- MACD
- ALMS 0.00
- RIGL 0.65
- Stochastic Oscillator
- ALMS 0.00
- RIGL 99.68
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.